Global

News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Corporate
Immunology
Bleeding Disorders
Hereditary Angioedema (HAE)
Pulmonary
Fluid Management
Resources

All Releases

07 September 2012 Avery-Landsteiner Prize for Immunology Awarded to Alain Fischer of Paris, France, by German Society for Immunology

The German Society for Immunology (DGfI) has awarded its 2012 Avery-Landsteiner Prize to Alain Fischer, M.D., Ph.D., of Paris, France, for his milestone discoveries and treatment developments in the management of hereditary immunodeficiencies. The Prize was presented at the European Congress for Immunology in Glasgow, Scotland today.

> Read More
01 August 2012 CSL Behring Awards Advocacy Grants to Patient Groups in
Six States: NC, CA, WA, PA, IL, NY

CSL Behring announced today that it has awarded six patient advocacy organizations in the U.S. with Local Empowerment for Advocacy Development (LEAD) grants totaling nearly $70,000. LEAD grants are awarded semiannually and are intended to help local patient organizations achieve their advocacy objectives by further developing an existing initiative or developing a new one.

> Read More
24 July 2012 Jeffrey Modell Foundation Opens Diagnostic Center for
Primary Immunodeficiencies at Midwest Immunology Clinic

The Jeffrey Modell Foundation (JMF), in partnership with CSL Behring, has designated the Midwest Immunology Clinic in Plymouth, Minnesota as a Jeffrey Modell Diagnostic Center for Primary Immunodeficiencies (PI). The Center is headed by Ralph Shapiro, M.D. and is devoted to the diagnosis, treatment and care of people who have PI and autoimmune disorders.

> Read More
11 July 2012 World’s First Intensive Study of Postpartum Women with von Willebrand Disease Shows Potential Risk of Delayed Hemorrhage, Despite Treatment

King of Prussia, PA – 11 July 2012 – Findings of a first-of-its-kind study of women with von Willebrand disease (VWD) show that current postpartum treatment strategies do not increase levels of von Willebrand factor (VWF) to normal range or even to the levels of women with milder, untreated VWD. VWF is a blood protein important for preventing postpartum hemorrhage. Results of this nationwide study are being presented at the World Federation of Hemophilia 2012 World Congress in Paris. This investigator-initiated study was supported by a $1.2 million unrestricted grant from CSL Behring.

> Read More
02 July 2012 CSL Behring Launches New Hizentra® Dosing Calculator App for Healthcare Professionals on the Move

UK – 2 July, 2012 – CSL Behring UK Ltd today announce the launch of the Hizentra Dosing Calculator App at The British Society for Allergy and Clinical Immunology (BSACI) Annual Scientific Meeting, taking place in Nottingham. The mobile app, for use on smart phones, is designed to assist healthcare professionals with dosage calculation when administering its product Hizentra (human normal immunoglobulin, SCIg).

> Read More
Page 25 of 53 First | Previous | Next | Last

Share
LinkedIn Twitter Facebook Google+